Answers are grounded in this paper and cite their sources.
Background Chronic pain is a frequent and often underestimated complication in patients with end-stage renal disease (ESRD) treated with hemodialysis. It significantly impairs quality of life and complicates therapeutic management. Despite its high prevalence, pain remains insufficiently assessed and treated in resource-limited settings, particularly in sub-Saharan Africa. This study aimed to describe the clinical, therapeutic, and longitudinal aspects of pain in hemodialysis patients at the National Hemodialysis Center of Donka (CNHD), Guinea. Methods We conducted an observational, longitudinal, prospective study with an analytical aim, from 1 August to 31 October 2025 at the CNHD. All chronic hemodialysis patients followed at the center during the study period were screened for the presence of pain; the 308 eligible patients were included, of whom 267 reported pain lasting more than 3 months and 41 reported no pain (comparison group). Patients with pain were assessed on three occasions during consecutive weekly visits (Week 1, Week 2, Week 3) using the Brief Pain Inventory (BPI) and the Visual Analog Scale (VAS, 0–10). Therapeutic changes (dose increase, drug substitution, stabilization) were recorded at each visit. Sociodemographic, clinical, biological, and dialysis-related variables were collected through a structured questionnaire and medical records. Normality of continuous variables was assessed with the Shapiro-Wilk test; comparisons used the Chi-square/Fisher’s exact test, the Wilcoxon rank-sum test (independent groups), and Friedman’s test (repeated measures over 3 weeks). Factors independently associated with pain were identified by multivariable logistic regression (significance threshold: p < 0.05). Results The prevalence of chronic pain was 86.7% (267/308). Pain was mainly intermittent (43.4%) or frequent (27.7%), predominantly of moderate intensity (VAS 3–5: 58.1%). It strongly affected daily life, particularly social activities (91.4%) and sleep (52.1%). Among patients with pain, 96.3% were receiving analgesic treatment, mostly paracetamol-based (73.9%). WHO step I analgesics predominated (73.5%). Despite treatment, only 11.2% of patients reported complete relief and 85.0% partial relief. In univariate analysis, female sex, vascular access type, and hemoglobin level were significantly associated with the presence of pain; after multivariable adjustment, only a low hemoglobin level remained independently associated with chronic pain (adjusted OR = 0.30 per 1 g/dl increase in hemoglobin; 95% CI 0.20–0.42; p < 0.001). Pain intensity differed significantly across the three weekly visits (Friedman’s test, p < 0.001), with a net shift toward higher severity categories between Week 1 and Week 3 (51.5% of patients worsened vs. 21.4% improved); individual trajectories were heterogeneous and depended on baseline severity, a pattern partly consistent with regression to the mean. Conclusions Chronic pain affects the vast majority of hemodialysis patients at the CNHD and remains insufficiently controlled by current analgesic strategies. These findings highlight the urgent need for systematic, standardized pain assessment, therapeutic protocols adapted to the constraints of renal impairment, and a multidisciplinary approach to improve the quality of life of hemodialysis patients in resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Fousseny et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: